Skip to main content

and
  1. Article

    Open Access

    Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells

    Immune checkpoint inhibitors are approved for the treatment of various tumors, but the response rate is not satisfactory in certain malignancies. Inhibitor of apoptosis proteins (IAP) ubiquitin-E3 ligase activ...

    Wentao Pan, Qiuyun Luo, Eric Liang, Mude Shi, Jian Sun in Cancer Cell International (2024)

  2. No Access

    Article

    PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis

    The accumulation of lipid peroxides is recognized as a determinant of the occurrence of ferroptosis. However, the sensors and amplifying process of lipid peroxidation linked to ferroptosis remain obscure. Here...

    Hai-Liang Zhang, Bing-**n Hu, Zhi-Ling Li, Tian Du, Jia-Lu Shan in Nature Cell Biology (2022)

  3. Article

    Open Access

    MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

    Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous clonal disease associated with unmet medical needs. Paralleling the pathology of other cancers, AML tumorigenesis and propagation can ...

    Douglas D. Fang, Qiuqiong Tang, Yanhui Kong, Tao Rong, Qixin Wang in Cell Death Discovery (2021)

  4. Article

    Open Access

    Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

    Imatinib shows limited efficacy in patients with gastrointestinal stromal tumors (GISTs) carrying secondary KIT mutations. HQP1351, an orally bioavailable multikinase BCR-ABL inhibitor, is currently in clinica...

    Xuechao Liu, Guangfeng Wang, **anglei Yan, Haibo Qiu, ** Min in Cell & Bioscience (2019)